These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 10597739)

  • 1. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
    Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
    Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
    Wrigley E; Weaver A; Jayson G; Ranson M; Renninson J; Prendiville J; Dobson M; Collins CD; Swindell R; Buckley CH; Radford JA; Crowther D
    Ann Oncol; 1996 Sep; 7(7):705-11. PubMed ID: 8905028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer.
    Fruscio R; Garbi A; Parma G; Lissoni AA; Garavaglia D; Bonazzi CM; Dell'anna T; Mangioni C; Milani R; Colombo N
    J Natl Cancer Inst; 2011 Feb; 103(4):347-51. PubMed ID: 21217084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
    Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB
    Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
    Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H
    Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
    Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
    Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
    Bolis G; Favalli G; Danese S; Zanaboni F; Mangili G; Scarabelli C; Tateo S; Valsecchi MG; Scarfone G; Richiardi G; Frigerio L; Melpignano M; Villa A; Parazzini F
    J Clin Oncol; 1997 May; 15(5):1938-44. PubMed ID: 9164205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.
    Conte PF; Gadducci A; Fioretti P; Bruzzone M; Brunetti I; Ragni N
    Eur J Gynaecol Oncol; 1994; 15(4):313-9. PubMed ID: 7957341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.